Key Takeaways
- The Pentagon has secured landmark agreements with seven tech leaders, including Nvidia (NVDA) and Microsoft (MSFT), to integrate artificial intelligence into classified military systems.
- Public sentiment regarding the Iran conflict has reached a critical tipping point, with 61% of Americans now labeling the war a "mistake" just three months after its commencement.
- Axsome Therapeutics (AXSM) received a major FDA expansion for its drug Auvelity, targeting Alzheimer’s agitation, a market with projected peak sales of up to $3 billion.
- South Korea’s Hanwha is aggressively scaling its U.S. presence, investing $5 billion to transform the Philly Shipyard into a high-capacity naval production hub for the U.S. Navy.
- U.S. housing aspirations have plummeted to a 13-year low, as only 25% of non-homeowners expect to purchase a property within the next five years.
Geopolitical Shifts and Rising Anti-War Sentiment
The USS Gerald R. Ford aircraft carrier has officially departed the Middle East following a record-setting 300-day deployment that included active operations against Iran. While the carrier returns to its home port in Virginia, the regional presence remains significant with the USS Abraham Lincoln and USS George H.W. Bush maintaining a fragile ceasefire.
Public support for the ongoing conflict has eroded at an unprecedented pace compared to previous American military engagements. A new Washington Post-ABC News poll reveals that 61% of Americans view the Iran war as a "mistake," a level of disapproval that took three years to reach during the Iraq War and six years during the Vietnam War. Analysts suggest that rising economic anxiety and fears of a war-induced recession are driving this rapid shift in public opinion.
Pentagon Accelerates AI Integration with Tech Giants
In a strategic move to maintain a technological edge, the U.S. military has reached deals with seven prominent tech companies to deploy AI on classified computer networks. The partners include Alphabet (GOOGL), Microsoft (MSFT), Amazon (AMZN), Nvidia (NVDA), OpenAI, SpaceX, and the startup Reflection.
These agreements aim to "augment warfighter decision-making" by reducing the time required to identify and strike targets. The exclusion of Anthropic from this list—currently embroiled in a legal battle with the Pentagon over ethical guardrails—highlights the administration's aggressive "American-first" approach to AI development.
Hanwha’s "Arms Empire" Expands to U.S. Shores
South Korea’s Hanwha Group is solidifying its status as a global defense powerhouse through its strategic control of the Philly Shipyard. The company has secured its first U.S. Navy contract to assist in the design of next-generation logistics ships, marking a milestone in U.S.-South Korean defense industrial cooperation.
Hanwha has pledged $5 billion in infrastructure investments to modernize the Philadelphia facility, with the goal of increasing annual production from 1.5 vessels to 20 vessels. This expansion is a cornerstone of the "Maritime Alliance for Shipbuilding Growth and Advancement" (MASGA), intended to revitalize the aging U.S. naval industrial base.
Axsome Therapeutics Secures Landmark FDA Approval
Axsome Therapeutics (AXSM) shares surged following the FDA’s approval of Auvelity for the treatment of agitation associated with Alzheimer’s dementia. This marks the first time a non-antipsychotic medication has been cleared for this indication, providing a safer alternative for the 7 million Americans affected by the disease.
The approval is expected to be a significant revenue driver, with William Blair projecting peak sales between $1.5 billion and $3 billion. By avoiding the "black box" safety warnings associated with traditional antipsychotics, Auvelity is positioned to become a first-line treatment in the geriatric psychiatry market.
Housing Market Pessimism Hits Record Highs
Economic pressure continues to weigh heavily on American consumers, as a recent Gallup poll shows homeownership intentions have crashed. Only 25% of non-homeowners expect to buy a home within the next five years, the lowest level recorded since the survey began in 2013.
The data reflects a "perfect storm" of high mortgage rates, record home prices, and tight inventory, with 67% of respondents stating that now is a "bad time to buy." Younger adults aged 18 to 34 are pulling back most sharply, signaling a long-term shift in the American real estate landscape.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.